Avior Bio

Avior Bio is a private, pre-revenue biotechnology company founded in 2018, specializing in advanced drug delivery. Its proprietary Speedit™ technology platform utilizes a process called compositional quenching to formulate lipophilic drugs into nanoparticles, significantly improving their absorption and efficacy. The company leverages its FDA-certified clinical manufacturing facility in Cary, NC, to support its own pipeline and potential partnerships, with an initial focus demonstrated through a collaboration with Tharimmune Inc. for pruritus therapy. Avior operates as a hybrid platform/therapeutics company, developing both its internal programs and offering its technology for external licensing and development services.

Speedit™, a patent-pending platform using compositional quenching to create cost-effective drug nanoparticles for improved bioavailability of lipophilic drugs in injectable, oral, and transmucosal film dosage forms.

Avior operates in a highly competitive field with numerous established drug delivery companies (e.g., Alkermes, Pacira) and many startups focusing on nano-formulations and solubility. Its success will depend on demonstrating cost-effectiveness, formulation flexibility, and superior bioavailability gains compared to existing technologies.